C24H22F2O5
Neat
428.43
209861-00-7; (3aR, 4R, 5R, 6aS)-4-((E)-3, 3-Difluoro-4-phenoxybut-1-en-1-yl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl benzoate; TF-BF; MFCD09833709; [(3aR, 4R, 5R, 6aS)-4-[(E)-3, 3-difluoro-4-phenoxybut-1-enyl]-2-oxo-3, 3a, 4, 5, 6, 6a-hexahydrocyclopenta[b]furan-5-yl] benzoate; C24H22F2O5; Tafluprost Impurity 15; Prostaglandin Impurity 38; (3aR, 4R, 5R, 6aS)-4-((E)-3, 3-Difluoro-4-phenoxybut-1-en-1-yl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-ylbenzoate; SCHEMBL7582851; ZGAZCXXMVLTEHN-PFPAMLNPSA-N; [(3aR, 4R, 5R, 6aS)-4-[(E)-3, 3-difluoro-4-phenoxy-but-1-enyl]-2-oxo-3, 3a, 4, 5, 6, 6a-hexahydrocyclopenta[b]furan-5-yl] benzoate; AKOS016004218; AC-28192; AS-79426; DB-200195; (3Ar, 4r, 5r, 6as)-5-(benzoyloxy)-4-[(1e)-3, 3-difluoro-4-phenoxy-1-buten-1-yl]hexahydro-2h-cyclopenta[b]furan-2-one; 2H-Cyclopenta[b]furan-2-one, 5-(benzoyloxy)-4-[(1E)-3, 3-difluoro-4-phenoxy-1-buten-1-yl]hexahydro-, (3aR, 4R, 5R and 6aS)-
[(3aR, 4R, 5R, 6aS)-4-[(E)-3, 3-difluoro-4-phenoxybut-1-enyl]-2-oxo-3, 3a, 4, 5, 6 and 6a-hexahydrocyclopenta[b]furan-5-yl] benzoate
InChI=1S/C24H22F2O5/c25-24(26,15-29-17-9-5-2-6-10-17)12-11-18-19-13-22(27)30-21(19)14-20(18)31-23(28)16-7-3-1-4-8-16/h1-12,18-21H,13-15H2/b12-11+/t18-,19-,20-,21+/m1/s1